| Market Capitalization (Millions $) |
0 |
| Shares
Outstanding (Millions) |
386 |
| Employees |
- |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
0 |
| Cash Flow (TTM) (Millions $) |
0 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Protokinetix Incorporated is a biotechnology company based in Canada. The company specializes in developing and commercializing innovative therapeutics for the treatment of diseases. Protokinetix's key focus is on a proprietary technology known as AAGP™ (Anti-Aging Glycoprotein), which has potential applications in various medical fields.
AAGP™ is a peptide-based molecule that has shown promising results in preclinical studies, demonstrating its effectiveness in protecting cells from damage and improving their function. Protokinetix is currently conducting further research and development to explore the potential therapeutic applications of AAGP™ in areas such as organ transplantation, cell and gene therapies, and regenerative medicine.
One of the notable advancements in Protokinetix's research is in the field of organ transplantation. The company has successfully demonstrated the ability of AAGP™ to extend the viability and function of organs, potentially reducing the need for organ donors and improving outcomes for patients awaiting transplants.
Protokinetix Incorporated is committed to advancing its technology and bringing novel therapeutics to market. The company collaborates with academic institutions, research organizations, and industry partners to accelerate the development and commercialization of its products. Overall, Protokinetix's innovative approach and focus on AAGP™ hold promise in the field of therapeutic interventions and improving patient outcomes.
Company Address: 109 W Main St Dalton 44618 OH
Company Phone Number: 434-5041 Stock Exchange / Ticker: PKTX
|
0.000%
3.74%